Ulquts Al Hindi (Sasereus sp) has Candidate Covid-19 drug Through  Regulation of Cytokines Produced by the Innate Immune System

Noviyanty Indjar Gama; Hajrah Hajrah; Helmi Helmi; Ysrafil Ysrafil

doi:10.30872/jtpc.v10i1.368

Authors

Noviyanty Indjar Gama Human Anatomy and Physiology Laboratory, Faculty of Pharmacy, Universitas Mulawarman, Indonesia Author
Hajrah Hajrah Pharmacodinamic Testing Laboratory, Faculty of Pharmacy, Universitas Mulawarman, Indonesia Author
Helmi Helmi Toxicology Laboratory, Faculty of Pharmacy, Universitas Mulawarman, Indonesia Author
Ysrafil Ysrafil Department of Pharmacotherapy, Faculty of Medicine, Universitas Palangka Raya, Indonesia Author

DOI:

https://doi.org/10.30872/jtpc.v10i1.368

Keywords:

COVID-19, Innate Immune, , Sars-cov-2, Ulquts Al Hindi, Inflammatory

Abstract

SARS-COV-2 virus is a new coronavirus variant that causes the severe acute respiratory syndrome. COVID-19 can cause abnormalities in various organs. It is due to increased levels of cytokines causing a cytokine storm. Cytokine storms occur due to an increase in the innate immune system to eliminate infectious agents. Activation of the production of inflammatory mediators causes pulmonary fibrosis, interstitial fluid infiltration, and impermeability in blood vessels. Qutshul al Hindi, or in Latin called Sausurea sp contains anti-inflammatory activity. However, the study about the definite benefit of bioactive in this plant against COVID-19 and their mechanism, especially to the immune system, needs more explanation. Therefore, this review discusses their mechanism against COVID-19 by activating immune cells. In the literature research, we approach the studies that examine the secondary metabolite of Qutshul al Hindi that is effective in activating and enhancing the immune response against covid 19. Our literature review shows that qutshul al Hindi (Sausurea sp) has anti-inflammatory activity by inhibiting expression and activity of cytokine proinflammation induced by the innate immune system. So that this plant is a promising herb as a therapeutic candidate for covid-19 by regulating the immune system to produce and activate cytokine pro-inflammatory.

Downloads

Download data is not yet available.

References

[1] World Health Organization, “Coronavirus Disease ( Covid-19 ) Outbreak : Rights , Roles and Responsibilities of Health Workers , Including Key Considerations for Occupational Safety,” World Health Organization (WHO), pp. 1–3, 2019.

[2] “Beranda | Covid19.go.id.” Accessed: Aug. 01, 2022. [Online]. Available: https://covid19.go.id/

[3] A. Parasher, “COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment,” Postgrad. Med. J., vol. 97, no. 1147, pp. 312–320, May 2021, doi: 10.1136/POSTGRADMEDJ-2020-138577.

[4] Y. Tang, J. Liu, D. Zhang, Z. Xu, J. Ji, and C. Wen, “Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies,” Front. Immunol., vol. 11, p. 1708, 2020, doi: 10.3389/fimmu.2020.01708.

[5] Moisés, R. de la Rica, M. Gonzalez-Freire, and M. Borges, “COVID-19: In the Eye of the Cytokine Storm,” Frontiers in Immunology | www.frontiersin.org, vol. 11, p. 558898, 2020, doi: 10.3389/fimmu.2020.558898.

[6] M. I. Mustafa, A. H. Abdelmoneim, E. M. Mahmoud, and A. M. Makhawi, “Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors,” Mediators Inflamm., vol. 2020, p. 7 page, 2020, doi: 10.1155/2020/8198963.

[7] P. Rangappa, “Cytokine storm and immunomodulation in covid-19,” Indian Journal of Critical Care Medicine, vol. 25, no. 11, pp. 1288–1291, 2021, doi: 10.5005/jp-journals-10071-24029.

[8] “Innate immune system - Autoimmunity - NCBI Bookshelf.” Accessed: Feb. 11, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK459455/

[9] S. Wan et al., “Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP),” medRxiv, p. 2020.02.10.20021832, Feb. 2020, doi: 10.1101/2020.02.10.20021832.

[10] C. Huang et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” The Lancet, vol. 395, no. 10223, pp. 497–506, 2020, doi: 10.1016/S0140-6736(20)30183-5.

[11] A. P. Yang, J. ping Liu, W. qiang Tao, and H. ming Li, “The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients,” Int. Immunopharmacol., vol. 84, Jul. 2020, doi: 10.1016/j.intimp.2020.106504.

[12] J. L. Schultze and A. C. Aschenbrenner, “COVID-19 and the human innate immune system,” Cell, vol. 184, no. 7, pp. 1671–1692, 2021, doi: 10.1016/j.cell.2021.02.029.

[13] P. R. S. Rodrigues et al., “Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology,” Oxf. Open Immunol., vol. 1, no. 1, p. 5, 2020, doi: 10.1093/oxfimm/iqaa005.

[14] G. I. Abd El-Rahman et al., “Saussurea lappa ethanolic extract attenuates triamcinolone acetonide-induced pulmonary and splenic tissue damage in rats via modulation of oxidative stress, inflammation, and apoptosis,” Antioxidants, vol. 9, no. 5, p. 396, 2020, doi: 10.3390/antiox9050396.

[15] M.-J. R. Howes, “Phytochemicals as Anti-inflammatory Nutraceuticals and Phytopharmaceuticals,” in Immunity and Inflammation in Health and Disease, Elsevier, 2018, pp. 363–388. doi: 10.1016/B978-0-12-805417-8.00028-7.

[16] M. Saif-Al-Islam, “Saussurea costus may help in the treatment of COVID-19,” Sohag Medical Journal, vol. 24, no. 3, p. page 12, Sep. 2020, doi: 10.21608/smj.2020.31144.1163.

[17] R. Lu et al., “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding,” The Lancet, vol. 395, no. 10224, pp. 565–574, Feb. 2020, doi: 10.1016/S0140-6736(20)30251-8.

[18] S. Zhang, L. Wang, and G. Cheng, “The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies,” Molecular Therapy, vol. 30, no. 5, pp. 1869–1884, 2022, doi: 10.1016/j.ymthe.2022.02.014.

[19] Y. Chen, Q. Liu, and D. Guo, “Emerging coronaviruses: Genome structure, replication, and pathogenesis,” J. Med. Virol., vol. 92, no. 4, pp. 418–423, Apr. 2020, doi: 10.1002/jmv.25681.

[20] M. Lotfi, M. R. Hamblin, and N. Rezaei, “COVID-19: Transmission, prevention, and potential therapeutic opportunities,” Clinica Chimica Acta, vol. 508, pp. 254–266, Sep. 2020, doi: 10.1016/j.cca.2020.05.044.

[21] Y. Wang, Z. Deng, and D. Shi, “How effective is a mask in preventing COVID‐19 infection?,” Med. Devices Sens., vol. 4, no. 1, Feb. 2021, doi: 10.1002/mds3.10163.

[22] K. L. Andrejko et al., “Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021,” MMWR Morb. Mortal. Wkly. Rep., vol. 71, no. 6, pp. 212–216, Feb. 2022, doi: 10.15585/mmwr.mm7106e1.

[23] M. A. Chowdhury, N. Hossain, M. A. Kashem, M. A. Shahid, and A. Alam, “Immune response in COVID-19: A review,” J. Infect. Public Health, vol. 13, no. 11, pp. 1619–1629, Nov. 2020, doi: 10.1016/j.jiph.2020.07.001.

[24] C. A. Biron, “Innate Immunity,” in Viral Pathogenesis, Third Edit., Elsevier, 2016, pp. 41–55. doi: 10.1016/B978-0-12-800964-2.00004-5.

[25] M. S. Diamond and T.-D. Kanneganti, “Innate immunity: the first line of defense against SARS-CoV-2,” Nat. Immunol., vol. 23, no. 2, pp. 165–176, Feb. 2022, doi: 10.1038/s41590-021-01091-0.

[26] A. J. Rodriguez-Morales et al., “Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis,” Travel Med. Infect. Dis., vol. 34, no. February, p. 101623, Mar. 2020, doi: 10.1016/j.tmaid.2020.101623.

[27] M. Mohanty, S. Varose, U. Sawant, and M. Fernandes, “Expression of innate immune response genes in upper airway samples of SARS-CoV-2 infected patients: A preliminary study,” Indian Journal of Medical Research, vol. 153, no. 5, p. 677, May 2021, doi: 10.4103/ijmr.IJMR_131_21.

[28] W. J. Wiersinga, A. Rhodes, A. C. Cheng, S. J. Peacock, and H. C. Prescott, “Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19),” JAMA, vol. 324, no. 8, p. 782, Aug. 2020, doi: 10.1001/jama.2020.12839.

[29] X. Cui et al., “Pulmonary Edema in COVID-19 Patients: Mechanisms and Treatment Potential,” Front. Pharmacol., vol. 12, p. 1444, Jun. 2021, doi: 10.3389/fphar.2021.664349.

[30] Integrated Taxonomic Information System - Report (ITIS), “Saussurea costus (Falc.) Lipsch.,” The Plant List v.1.1.

[31] R. K. Nadda, A. Ali, R. C. Goyal, P. K. Khosla, and R. Goyal, “Aucklandia costus (Syn. Saussurea costus): Ethnopharmacology of an endangered medicinal plant of the himalayan region,” J. Ethnopharmacol., vol. 263, p. 113199, Dec. 2020, doi: 10.1016/j.jep.2020.113199.

[32] C. Opin Complement Alternat Med et al., “Research Progress on Active Ingredients and Pharmacologic Properties of Saussurea lappa,” Curr Opin Complement Alternat Med, vol. 1, no. 1, p. 5, 2014.

[33] M. M. Pandey, S. Rastogi, and A. K. S. Rawat, “Saussurea costus: Botanical, chemical and pharmacological review of an ayurvedic medicinal plant,” J. Ethnopharmacol., vol. 110, no. 3, pp. 379–390, Apr. 2007, doi: 10.1016/J.JEP.2006.12.033.

[34] M. Ahmad et al., “Useful Medicinal Flora Enlisted in Holy Quran and Ahadith,” J. Agric. & Environ. Sci, vol. 5, no. 1, pp. 126–140, 2009.

[35] R. Singh, K. K. Chahal, and N. Singla, “Chemical composition and pharmacological activities of Saussurea lappa : A review,” J. Pharmacogn. Phytochem., vol. 6, no. 4, pp. 1298–1308, Jan. 2017, doi: 2278-4136.

[36] R. Hassan and M. H. Masoodi, “Saussurea lappa: A Comprehensive Review on its Pharmacological Activity and Phytochemistry,” Current Traditional Medicine, vol. 6, no. 1, pp. 13–23, Jun. 2019, doi: 10.2174/2215083805666190626144909.

[37] Z. L. Liu, Q. He, S. S. Chu, C. F. Wang, S. S. Du, and Z. W. Deng, “Essential oil composition and larvicidal activity of Saussurea lappa roots against the mosquito Aedes albopictus (Diptera: Culicidae),” Parasitol. Res., vol. 110, no. 6, pp. 2125–2130, Jun. 2012, doi: 10.1007/s00436-011-2738-0.

[38] A. A. Damre, A. S. Damre, and M. N. Saraf, “Evaluation of sesquiterpene lactone fraction of Saussurea lappa on transudative, exudative and proliferative phases of inﬂammation,” Phytotherapy Research, vol. 17, no. 7, pp. 722–725, Aug. 2003, doi: 10.1002/PTR.1152.

[39] X. Huang et al., “OncoTargets and Therapy Dovepress luteolin decreases invasiveness, deactivates sTaT3 signaling, and reverses interleukin-6 induced epithelial-mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells,” Onco. Targets. Ther., vol. 8, pp. 2989–3001, 2015, doi: 10.2147/OTT.S91511.

[40] B. R. Chhabra, N. M. Ahuja, M. K. Bhullar, and P. S. Kalsi, “Some C-3 oxygenated guaianolides from Saussurea lappa,” Fitoterapia, vol. 69, no. 3, pp. 274–275, 1998.

[41] S. KALSI, S. SHARMA, and G. KAUR, “Isodehydrocostus lactone and isozaluzanin C, two guaianolides from Saussurea lappa,” Phytochemistry, vol. 22, no. 9, pp. 1993–1995, 1983, doi: 10.1016/0031-9422(83)80031-4.

[42] A. Asaba, T. Hattori, K. Mogi, and T. Kikusui, “Sexual attractiveness of male chemicals and vocalizations in mice,” Front. Neurosci., vol. 8, no. 8 JUL, Aug. 2014, doi: 10.3389/fnins.2014.00231.

[43] C.-M. Sun, W.-J. Syu, M.-J. Don, J.-J. Lu, and G.-H. Lee, “Cytotoxic Sesquiterpene Lactones from the Root of Saussurea l appa,” J. Nat. Prod., vol. 66, no. 9, pp. 1175–1180, Sep. 2003, doi: 10.1021/np030147e.

[44] M. YOSHIKAWA, S. HATAKEYAMA, Y. INOUE, and J. YAMAHARA, “Saussureamines A, B, C, D, and E, new anti-ulcer principles from Chinese Saussureae Radix.,” Chem. Pharm. Bull. (Tokyo)., vol. 41, no. 1, pp. 214–216, Jan. 1993, doi: 10.1248/cpb.41.214.

[45] R. S. Dhillon, P. S. Kalsi, W. P. Singh, V. K. Gautam, and B. R. Chhabra, “Guaianolide from Saussurea lappa,” Phytochemistry, vol. 26, no. 4, pp. 1209–1210, Jan. 1987, doi: 10.1016/S0031-9422(00)82384-5.

[46] B. R. Chhabra, S. Gupta, R. S. Dhillon, and P. S. Kalsi, “Minor sesquiterpene lactones from Saussurea lappa roots,” Fitoterapia, vol. 68, no. 5, pp. 470–471, 1997.

[47] S. Kumar, N. M. Ahuja, G. S. Juawanda, and B. R. Chhabra, “New guaianolides from Saussurea lappa roots,” Fitoterapia, vol. 66, no. 3, p. 287, 1995.

[48] H. Yin et al., “Two New Sesquiterpene Lactones with the Sulfonic Acid Group from Saussurea lappa.,” ChemInform, vol. 36, no. 52, pp. 841–842, Dec. 2005, doi: 10.1002/chin.200552156.

[49] J. Cho et al., “Inhibitory Effect of Sesquiterpene Lactones from Saussurea lappa on Tumor Necrosis Factor-α Production in Murine Macrophage-Like Cells,” Planta Med., vol. 64, no. 07, pp. 594–597, Oct. 1998, doi: 10.1055/s-2006-957528.

[50] G. Blay, L. Cardona, B. Garcia, and J. R. Pedro, “A short synthesis of (+)-colartin and (+)-arbusculin a from (−)-santonin,” J. Nat. Prod., vol. 56, no. 10, pp. 1723–1727, Oct. 1993, doi: 10.1021/np50100a010.

[51] J.-S. Kim, H.-J. Chi, S.-Y. Chang, K.-W. Ha, and S.-S. Kang, “Isolation and quantitative determination of costunolide from Saussurea root,” Korean Journal of Pharmacognosy, vol. 30, no. 1, pp. 48–53, 1999.

[52] R. Mohamed, O. Alaagib, S. Mohamed, and H. Ayoub, “The Pharma Innovation Journal 2015; 4(2): 73-76 On the chemical composition and antibacterial activity of Saussurea lappa (Asteraceae),” The Pharma Innovation Journal, vol. 4, no. 2, pp. 73–76, 2015.

[53] K. S. Rao, G. V. Babu, and Y. V. Ramnareddy, “Acylated flavone glycosides from the roots of Saussurea lappa and their antifungal activity,” Molecules, vol. 12, no. 3, pp. 328–344, 2007, doi: 10.3390/12030328.

[54] T. A. Trinh et al., “Effect of Herbal Formulation on Immune Response Enhancement in RAW 264.7 Macrophages,” Biomolecules, vol. 10, no. 3, p. 424, Mar. 2020, doi: 10.3390/biom10030424.

[55] S. R. Prawiro et al., “Generating responses immune in cellular and humoral treatment with epitope spike, epitope envelope protein, and epitope membrane protein sars-cov-2, honey, saussurea lappa, and nigella sativa,” Afr. J. Infect. Dis., vol. 15, no. 2, pp. 23–30, 2021, doi: 10.21010/ajidv15n2S.3.

[56] A. Sarwar and H. Enbergs, “Effects of Saussurea lappa roots extract in ethanol on leukocyte phagocytic activity, lymphocyte proliferation and interferon-gamma (IFN-gamma).,” Pak. J. Pharm. Sci., vol. 20, no. 3, pp. 175–179, Jul. 2007.

[57] B. Gierlikowska, W. Gierlikowski, and U. Demkow, “Alantolactone Enhances the Phagocytic Properties of Human Macrophages and Modulates Their Proinflammatory Functions,” Front. Pharmacol., vol. 11, no. September, pp. 1–13, 2020, doi: 10.3389/fphar.2020.01339.

[58] G. I. Lee et al., “Inhibitory effects of oriental herbal medicines on IL-8 induction in lipopolysaccharide-activated rat macrophages,” Planta Med., vol. 61, no. 1, pp. 26–30, 1995, doi: 10.1055/S-2006-957992/BIB.

[59] H. J. Lee et al., “A sesquiterpene, dehydrocostus lactone, inhibits the expression of inducible nitric oxide synthase and TNF-α in LPS-activated macrophages,” Planta Med., vol. 65, no. 2, pp. 104–108, 1999, doi: 10.1055/S-1999-13968/BIB.

[60] M. Jin, H. J. Lee, J. H. Ryu, and K. S. Chung, “Inhibition of LPS-induced NO production and NF-kappaB activation by a sesquiterpene from Saussurea lappa,” Arch. Pharm. Res., vol. 23, no. 1, pp. 54–58, 2000, doi: 10.1007/BF02976467.

[61] J. Y. Cho et al., “Inhibitory effect of sesquiterpene lactones from Saussurea lappa on tumor necrosis factor-α production in murine macrophage-like cells,” Planta Med., vol. 64, no. 7, pp. 594–597, 1998, doi: 10.1055/S-2006-957528/BIB.

[62] J. Y. Cho, K. U. Baik, J. H. Jung, and M. H. Park, “In vitro anti-inflammatory effects of cynaropicrin, a sesquiterpene lactone, from Saussurea lappa,” Eur. J. Pharmacol., vol. 398, no. 3, pp. 399–407, Jun. 2000, doi: 10.1016/S0014-2999(00)00337-X.

[63] H. Matsuda, I. Toguchida, K. Ninomiya, T. Kageura, T. Morikawa, and M. Yoshikawa, “Effects of sesquiterpenes and amino acid-sesquiterpene conjugates from the roots of Saussurea lappa on inducible nitric oxide synthase and heat shock protein in lipopolysaccharide-activated macrophages.,” Bioorg. Med. Chem., vol. 11, no. 5, pp. 709–715, Mar. 2003, doi: 10.1016/S0968-0896(02)00471-6.

[64] J. S. Kang, Y. D. Yoon, K. H. Lee, S. K. Park, and H. M. Kim, “Costunolide inhibits interleukin-1β expression by down-regulation of AP-1 and MAPK activity in LPS-stimulated RAW 264.7 cells,” Biochem. Biophys. Res. Commun., vol. 313, no. 1, pp. 171–177, Jan. 2004, doi: 10.1016/J.BBRC.2003.11.109.

[65] X. Dang et al., “Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways,” Respir. Res., vol. 21, no. 1, pp. 1–11, Apr. 2020, doi: 10.1186/S12931-020-01358-4/FIGURES/9.

[66] A. De Stefano et al., “Anti-Inflammatory and Proliferative Properties of Luteolin-7-O-Glucoside,” Int. J. Mol. Sci., vol. 22, no. 3, pp. 1–19, Feb. 2021, doi: 10.3390/IJMS22031321.

[67] [J. Michaud-Levesque, N. Bousquet-Gagnon, and R. Béliveau, “Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration,” Exp. Cell Res., vol. 318, no. 8, pp. 925–935, May 2012, doi: 10.1016/J.YEXCR.2012.02.017.

[68] [A. Mukherjee and A. R. Khuda-Bukhsh, “Quercetin Down-regulates IL-6/STAT-3 Signals to Induce Mitochondrial-mediated Apoptosis in a Nonsmall- cell Lung-cancer Cell Line, A549,” J. Pharmacopuncture, vol. 18, no. 1, p. 19, Mar. 2015, doi: 10.3831/KPI.2015.18.002.

[69] E. M. Choi and Y. S. Lee, “Luteolin suppresses IL-1β-induced cytokines and MMPs production via p38 MAPK, JNK, NF-kappaB and AP-1 activation in human synovial sarcoma cell line, SW982,” Food and Chemical Toxicology, vol. 48, no. 10, pp. 2607–2611, Oct. 2010, doi: 10.1016/J.FCT.2010.06.029.

[70] C. W. Liu et al., “Luteolin inhibits viral-induced inflammatory response in RAW264.7 cells via suppression of STAT1/3 dependent NF-κB and activation of HO-1.,” Free Radic. Biol. Med., vol. 95, pp. 180–189, Mar. 2016, doi: 10.1016/J.FREERADBIOMED.2016.03.019.

[71] W. Wang et al., “Efficiency comparison of apigenin-7-O-glucoside and trolox in antioxidative stress and anti-inflammatory properties,” 2020, doi: 10.1111/jphp.13347.

[72] M. Comalada et al., “Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: Analysis of the structure–activity relationship,” Biochem. Pharmacol., vol. 72, no. 8, pp. 1010–1021, Oct. 2006, doi: 10.1016/J.BCP.2006.07.016.

[73] R. H. Patil et al., “Anti-Inflammatory Effect of Apigenin on LPS-Induced Pro-Inflammatory Mediators and AP-1 Factors in Human Lung Epithelial Cells,” Inflammation, vol. 39, no. 1, pp. 138–147, Feb. 2016, doi: 10.1007/S10753-015-0232-Z/METRICS.

[74] P. Sittisart, B. Chitsomboon, and N. E. Kaminski, “Pseuderanthemum palatiferum leaf extract inhibits the proinflammatory cytokines, TNF-α and IL-6 expression in LPS-activated macrophages,” Food and Chemical Toxicology, vol. 97, pp. 11–22, Nov. 2016, doi: 10.1016/J.FCT.2016.08.021.

[75] J. H. Lee, H. Y. Zhou, S. Y. Cho, Y. S. Kim, Y. S. Lee, and C. S. Jeong, “Anti-inflammatory mechanisms of apigenin: Inhibition of cyclooxygenase-2 expression, adhesion of monocytes to human umbilical vein endothelial cells, and expression of cellular adhesion molecules,” Arch. Pharm. Res., vol. 30, no. 10, pp. 1318–1327, Oct. 2007, doi: 10.1007/BF02980273/METRICS.

[76] G. L. Chen, M. X. Fan, J. L. Wu, N. Li, and M. Q. Guo, “Antioxidant and anti-inflammatory properties of flavonoids from lotus plumule,” Food Chem., vol. 277, pp. 706–712, Mar. 2019, doi: 10.1016/J.FOODCHEM.2018.11.040.

[77] H. Yoo, S. K. Ku, Y. D. Baek, and J. S. Bae, “Anti-inflammatory effects of rutin on HMGB1-induced inflammatory responses in vitro and in vivo,” Inflammation Research, vol. 63, no. 3, pp. 197–206, Mar. 2014, doi: 10.1007/S00011-013-0689-X/METRICS.

[78] W. Alam, H. Khan, M. A. Shah, O. Cauli, and L. Saso, “molecules Kaempferol as a Dietary Anti-Inflammatory Agent: Current Therapeutic Standing”, doi: 10.3390/molecules25184073.

[79] R. Zhang et al., “Kaempferol ameliorates H9N2 swine influenza virus-induced acute lung injury by inactivation of TLR4/MyD88-mediated NF-κB and MAPK signaling pathways,” Biomedicine & Pharmacotherapy, vol. 89, pp. 660–672, May 2017, doi: 10.1016/J.BIOPHA.2017.02.081.

[80] X. L. Tang et al., “Protective Effect of Kaempferol on LPS plus ATP-Induced Inflammatory Response in Cardiac Fibroblasts,” Inflammation, vol. 38, no. 1, pp. 94–101, Feb. 2015, doi: 10.1007/S10753-014-0011-2/METRICS.

[81] C. L. L. Saw et al., “The berry constituents quercetin, kaempferol, and pterostilbene synergistically attenuate reactive oxygen species: Involvement of the Nrf2-ARE signaling pathway,” Food and Chemical Toxicology, vol. 72, pp. 303–311, Oct. 2014, doi: 10.1016/J.FCT.2014.07.038.

[82] S. Y. Nam, H. J. Jeong, and H. M. Kim, “Kaempferol impedes IL-32-induced monocyte-macrophage differentiation.,” Chem. Biol. Interact., vol. 274, pp. 107–115, Jul. 2017, doi: 10.1016/J.CBI.2017.07.010.